Overview
Status
Active
Registry date
2021-06-25
Share capital
5,000.00 PLN
Registered address
ul. Żegańska 21/23, 04-713 Warszawa, Poland
Email
Electronic delivery address
AE:PL-92840-94290-AREGR-29
Financials
Data for 2025 is not shown: the filed document is not a financial statement (e.g. a resolution or a management report).
The statements for 2021–2024 report only zeros (no activity), so those years are not shown in the charts.
Industry
Authorized Representatives
Wojciech Pawelec – President of the Management Board
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 100 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2026-03-01.
57 1020 2313 0000 3802 1191 3177
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Medif sp. z o.o.sp. k. | $13,126,958.83 | medif.com | ||
| American Way Polska Miłkowskisp. k. | $1,893,749.17 | americanwaypolska.pl | ||
| Brandexsp. z o.o. | $1,958,619.75 | brandex.pl | ||
| PUBE Globalsp. z o.o. | $1,777,827.09 | pubeglobal.com | ||
| Black & Whitesp. z o.o. | $154,866.36 | polonus.pl | ||
| Osteoprofsp. z o.o. | $72,065.80 | osteoprof.pl | ||
| EDGE Pharmasp. z o.o. | $19,855.64 | edgepharma.eu | ||
| PolfaS.A. | – | polfa.eu | ||
| Biodermaticsp. j. | – | biodermatic.com | ||
| Megamedicasp. z o.o. | – | megamedica.pl |
FAQ
The main business activity of Ovipharm focuses on wholesale of pharmaceutical goods.
The company was registered in the Polish National Court Register (KRS) on June 25, 2021.
The headquarters is located at: ul. Żegańska 21, 04-713 Warszawa.
The management board consists of: Wojciech Pawelec (President of the Management Board).
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
Last updated: 2026-10-07